151 related articles for article (PubMed ID: 31702411)
21. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
[TBL] [Abstract][Full Text] [Related]
22. Impact of Direct-Acting Antiviral Therapy on Liver Fibrosis Regression among People with Chronic HCV Infection: Results from a Real-Life Cohort in Patients Who Achieved Sustained Virological Response.
García-Ros A; Morán S; Núñez V; García-Ros G; Ruiz G; García-Solano J
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109770
[No Abstract] [Full Text] [Related]
23. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
Labarga P; Fernandez-Montero JV; Barreiro P; Pinilla J; Vispo E; de Mendoza C; Plaza Z; Soriano V
J Viral Hepat; 2014 Jul; 21(7):475-9. PubMed ID: 24750394
[TBL] [Abstract][Full Text] [Related]
24. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
25. Chronic Hepatitis C Treatment with Direct-Acting Antiviral Agents in a Real-Life Setting.
Chirino-Sprung RA; Dehesa M; Wolpert E; Corona-Lau C; García-Juarez I; Sánchez-Ávila JF; Moctezuma-Velázquez C; Kershenobich D
Rev Invest Clin; 2016; 68(4):203-12. PubMed ID: 27623039
[TBL] [Abstract][Full Text] [Related]
26. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
Ogasawara N; Kobayashi M; Akuta N; Kominami Y; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Suzuki F; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2018 Feb; 90(2):313-319. PubMed ID: 28906010
[TBL] [Abstract][Full Text] [Related]
27. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
28. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis.
Masetti C; Lionetti R; Lupo M; Siciliano M; Giannelli V; Ponziani FR; Teti E; Dell'Unto C; Francioso S; Brega A; Montalbano M; Visco-Comandini U; Taibi C; Galati G; Vespasiani Gentilucci U; Picardi A; Andreoni M; Pompili M; Pellicelli AM; D'Offizi G; Gasbarrini A; De Santis A; Angelico M
J Viral Hepat; 2018 Dec; 25(12):1493-1500. PubMed ID: 30112854
[TBL] [Abstract][Full Text] [Related]
29. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P
Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329
[TBL] [Abstract][Full Text] [Related]
30. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
31. Noninvasive Assessment of Fibrosis Regression after Direct-acting Antiviral Treatment in Hepatitis C Virus Patients.
Davidov Y; Kleinbaum Y; Inbar Y; Cohen-Ezra O; Veitsman E; Weiss P; Likhter M; Berdichevski T; Katsherginsky S; Hassid A; Tsaraf K; Silverberg D; Ben Ari Z
Isr Med Assoc J; 2021 Dec; 23(12):794-800. PubMed ID: 34954919
[TBL] [Abstract][Full Text] [Related]
32. Prediction of efficacy of interferon treatment of chronic hepatitis C and occurrence of HCC after interferon treatment by a new classification.
Kim KI; Sasase N; Taniguchi M; Mita K; Kim SR; Tanaka K; Hayashi Y
Intervirology; 2005; 48(1):52-8. PubMed ID: 15785090
[TBL] [Abstract][Full Text] [Related]
33. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Tada T; Kumada T; Toyoda H; Mizuno K; Sone Y; Kataoka S; Hashinokuchi S
J Gastroenterol Hepatol; 2017 Dec; 32(12):1982-1988. PubMed ID: 28299813
[TBL] [Abstract][Full Text] [Related]
34. Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals.
Giannini EG; Crespi M; Demarzo M; Bodini G; Furnari M; Marabotto E; Torre F; Zentilin P; Savarino V
Eur J Clin Invest; 2019 Mar; 49(3):e13056. PubMed ID: 30474209
[TBL] [Abstract][Full Text] [Related]
35. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C.
Rutter K; Stättermayer AF; Beinhardt S; Scherzer TM; Steindl-Munda P; Trauner M; Ferenci P; Hofer H
Aliment Pharmacol Ther; 2015 Mar; 41(6):521-31. PubMed ID: 25616017
[TBL] [Abstract][Full Text] [Related]
36. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
37. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection.
Lledó GM; Carrasco I; Benítez-Gutiérrez LM; Arias A; Royuela A; Requena S; Cuervas-Mons V; de Mendoza C
AIDS; 2018 Oct; 32(16):2347-2352. PubMed ID: 30096074
[TBL] [Abstract][Full Text] [Related]
38. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C.
Stasi C; Arena U; Zignego AL; Corti G; Monti M; Triboli E; Pellegrini E; Renzo S; Leoncini L; Marra F; Laffi G; Milani S; Pinzani M
Dig Liver Dis; 2013 Oct; 45(10):840-3. PubMed ID: 23660078
[TBL] [Abstract][Full Text] [Related]
40. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
Tamaki N; Higuchi M; Kurosaki M; Kirino S; Osawa L; Watakabe K; Wang W; Okada M; Shimizu T; Takaura K; Takada H; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
J Viral Hepat; 2019 Jul; 26(7):893-899. PubMed ID: 30974045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]